$SEEL News Article - Seelos Therapeutics Doses First Patient in Part 2 of a Registrational Study of SLS-002 (Intranasal Racemic Ketamine) for Acute Suicidal Ideation and Behavior in Patients with Major Depressive Disorder
https://marketwirenews.com/news-releases/seel...43213.html